13F-HR filed by Opaleye Management Inc.
Opaleye Management Inc. filed this 13F-HR for the quarter ended 2017-06-30, filed 2017-08-14, with 41 holding rows worth $239,398,000.
- Accession
- 0001493152-17-009239
- Filer
- CIK 1595855
- Filed
- 2017-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2017
A holdings report, 41 entries on the cover page, a total value of $239,398,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $239,398,000 with VALUE read as thousands by filing date, 13F file number 028-15896. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 09627Y109 | COM | 880,000 | $44,589,000 | thousands by filing date | |
| AXOGEN INC | 05463X106 | COM | 1,970,000 | $32,997,000 | thousands by filing date | |
| FIBROGEN INC | 31572Q808 | COM | 360,000 | $11,628,000 | thousands by filing date | |
| LOXO ONCOLOGY INC | 548862101 | COM | 130,000 | $10,425,000 | thousands by filing date | |
| STRONGBRIDGE BIOPHARMA PLC | G85347105 | SHS USD | 1,180,000 | $8,437,000 | thousands by filing date | |
| CODEXIS INC | 192005106 | COM | 1,470,000 | $8,011,000 | thousands by filing date | |
| IMMUNOMEDICS INC | 452907108 | COM | 900,000 | $7,947,000 | thousands by filing date | |
| MOMENTA PHARMACEUTICALS INC | 60877T100 | COM | 450,000 | $7,605,000 | thousands by filing date | |
| THERAVANCE BIOPHARMA INC | G8807B106 | COM | 180,000 | $7,171,000 | thousands by filing date | |
| CYTOMX THERAPEUTICS INC | 23284F105 | COMMON STOCK | 460,000 | $7,130,000 | thousands by filing date | |
| CHIMERIX INC COM | 16934W106 | Stock | 1,280,000 | $6,976,000 | thousands by filing date | |
| NOVELION THERAPEUTICS INC | 67001K202 | COM NEW | 750,000 | $6,922,000 | thousands by filing date | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 130,000 | $6,688,000 | thousands by filing date | |
| CORIUM INTL INC | 21887L107 | COM | 715,000 | $5,334,000 | thousands by filing date | |
| FOAMIX PHARMACEUTICALS LTD | M46135105 | SHS | 1,135,000 | $5,266,000 | thousands by filing date | |
| SANGAMO THERAPEUTICS INC | 800677106 | COM | 580,000 | $5,104,000 | thousands by filing date | |
| ADAMAS PHARMACEUTICALS INC | 00548A106 | COM | 290,000 | $5,072,000 | thousands by filing date | |
| EAGLE PHARMACEUTICALS INC | 269796108 | COM | 60,000 | $4,733,000 | thousands by filing date | |
| PROTHENA CORP PLC SHS | G72800108 | Stock | 85,000 | $4,600,000 | thousands by filing date | |
| ENANTA PHARMACEUTICALS INC | 29251M106 | COM | 100,000 | $3,598,000 | thousands by filing date | |
| NEURODERM LTD | M74231107 | ORD SHS | 120,300 | $3,597,000 | thousands by filing date | |
| ACCELERON PHARMA INC | 00434H108 | COM | 100,000 | $3,039,000 | thousands by filing date | |
| AUDENTES THERAPEUTICS INC. | 05070R104 | Common Stock | 150,000 | $2,869,000 | thousands by filing date | |
| IMPRIMIS PHARMA IMMY | 45323A201 | COMMON | 895,000 | $2,864,000 | thousands by filing date | |
| ARDELYX INC | 039697107 | COM | 546,500 | $2,787,000 | thousands by filing date | |
| TETRAPHASE PHARMACEUTICALS INC | 88165N105 | COMMON STOCK | 330,000 | $2,353,000 | thousands by filing date | |
| WAVE LIFE SCIENCES LTD SHS | Y95308105 | Stock | 125,000 | $2,325,000 | thousands by filing date | |
| ARATANA THERAPEUTICS INC | 03874P101 | COM | 350,200 | $2,279,000 | thousands by filing date | |
| XOMA ROYALTY CORPORATION | 98419J206 | COMMON STOCK | 317,200 | $2,217,000 | thousands by filing date | |
| SYNLOGIC | 60470J103 | Stock | 1,148,100 | $1,917,000 | thousands by filing date | |
| SYROS PHARMACEUTICALS INC | 87184Q107 | COM | 109,500 | $1,762,000 | thousands by filing date | |
| Adobe Systems Inc | 98979H103 | COM | 1,225,000 | $1,727,000 | thousands by filing date | |
| TONIX PHARMACEUTICALS HOLDING | 890260201 | COM NEW | 370,000 | $1,602,000 | thousands by filing date | |
| PROTALIX BIOTHERAPEUTICS INC | 74365AAB7 | NOTE 4.500% 9/1 | 1,835,000 | $1,537,000 | thousands by filing date | |
| EDGE THERAPEUTICS INC | 279870109 | COM | 130,000 | $1,334,000 | thousands by filing date | |
| ARQULE INC | 04269E107 | COM | 970,000 | $1,203,000 | thousands by filing date | |
| GLOBAL BLOOD THERAPEUTICS USD | 37890U108 | COM | 40,000 | $1,094,000 | thousands by filing date | |
| INTRA CELLULAR THERAPIES INC | 04611X101 | COM | 85,000 | $1,056,000 | thousands by filing date | |
| SUNESIS PHARMACEUTICALS INC | 867328700 | COM | 380,000 | $1,026,000 | thousands by filing date | |
| NEOS THERAPEUTICS INC | 64052L106 | COM | 50,000 | $365,000 | thousands by filing date | |
| BIOLINERX LTD-SPONS ADR | 09071M106 | SPON | 250,000 | $212,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001493152-17-009239 | this filing | 2017-08-14 | acceptance time not in the bulk data set |